The biology of neoadjuvant chemotherapy for breast cancer
- PMID: 12237246
- DOI: 10.1677/erc.0.0090183
The biology of neoadjuvant chemotherapy for breast cancer
Abstract
Neoadjuvant/pre-surgical medical therapy of breast cancer provides a unique opportunity to derive biological information related to tumour response. Large clinical trials of neoadjuvant chemotherapy have established that pathological complete remission is an independent predictor of improved disease-free survival. Clinical response has been found to parallel substantial reductions in the proliferation of breast cancer cells. Increased apoptosis also occurs, but it is not closely associated with response. Numerous biological markers such as p53, bcl-2, oestrogen receptor (ER) and HER2 have been assessed for their possible role in chemoresistance/response, but the data are not clear at this stage. Continuing work using cDNA microarrays may yield new, more reliable indices of likely response and an improved insight into biological processes related to chemotherapeutic response.
Similar articles
-
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29233559
-
Neoadjuvant chemotherapy in breast cancer.Br J Surg. 2005 Jan;92(1):14-23. doi: 10.1002/bjs.4840. Br J Surg. 2005. PMID: 15635596 Review.
-
alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.Breast Cancer Res Treat. 2008 Oct;111(3):411-7. doi: 10.1007/s10549-007-9796-0. Epub 2007 Oct 30. Breast Cancer Res Treat. 2008. PMID: 17968656
-
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.Breast Cancer Res Treat. 2010 Jan;119(2):315-23. doi: 10.1007/s10549-009-0329-x. Epub 2009 Feb 27. Breast Cancer Res Treat. 2010. PMID: 19247830
-
Neoadjuvant chemotherapy for breast cancer.Ann Med. 2000 Feb;32(1):43-50. doi: 10.3109/07853890008995909. Ann Med. 2000. PMID: 10711577 Review.
Cited by
-
Demystifying basal-like breast carcinomas.J Clin Pathol. 2007 Dec;60(12):1328-32. doi: 10.1136/jcp.2006.041731. Epub 2007 May 11. J Clin Pathol. 2007. PMID: 17496191 Free PMC article. Review.
-
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.BMC Cancer. 2012 Jan 4;12:4. doi: 10.1186/1471-2407-12-4. BMC Cancer. 2012. PMID: 22217342 Free PMC article.
-
State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.Ger Med Sci. 2005 Sep 13;3:Doc08. Ger Med Sci. 2005. PMID: 19675725 Free PMC article.
-
Methylene Blue-Based Near-Infrared Fluorescence Imaging for Breast Cancer Visualization in Resected Human Tissues.Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819894331. doi: 10.1177/1533033819894331. Technol Cancer Res Treat. 2019. PMID: 31835962 Free PMC article.
-
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.BMC Cancer. 2011 Aug 7;11:341. doi: 10.1186/1471-2407-11-341. BMC Cancer. 2011. PMID: 21819622 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous